Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells

Molecular Cancer Research

Volumn 11, Issue 2, 2013, Pages 140-148

  Minami, Daisuke ^a   Takigawa, Nagio ^b   Takeda, Hiromasa ^a   Takata, Minoru ^c   Ochi, Nobuaki ^a   Ichihara, Eiki ^a   Hisamoto, Akiko ^a   Hotta, Katsuyuki ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PTEN PHOSPHOHYDROLASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874411631     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0401     Document Type: Article

References (45)

1. Jin-xue He, Chun-hao Yang, Ze-hong Miao. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacologica Sinica 2010;31:1172-80.
2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
4. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
5. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
6. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-44.
7. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010;376:245-51.
8. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triplenegative breast cancer cell lines to poly (ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010;70:7970-80.
9. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-50.
10. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
11. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN, et al. BRCA1-and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007;67:7078-81.
12. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009;69:3589-96.
13. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol 2011;5:387-93.
14. Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly (ADPribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem 2008;16: 10121-8.
15. Zhu G, Chang P, Lippard SJ. Recognition of platinum-DNA damage by poly (ADP-ribose) polymerase-1. Biochemistry 2010;49:6177-83.
16. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14:3916-25.
17. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patientderived ovarian cancer tissue xenografts. Clin Cancer Res 2011;17: 783-91.
18. Ashworth A. A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90.
19. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-14.
20. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010;69:279-83.
21. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-61.
22. Soria JC, Lee HY, Lee JI,Wang L, Issa JP,Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-84.
23. Marsit CJ, Zheng S, Aldape K, HindsPW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005;36:768-76.
24. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-70.
25. Yin Y, Shen WH. PTEN: A new guardian of the genome. Oncogene 2008;27:5443-53.
26. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN Loss compromises homologous recombination repair in astrocytes: Implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010;70:5457-64.
27. Takeda H, Ohashi K, Kataoka I, Ichihara E, Takigawa N, Tanimoto M, et al. Efficacy of vandetanib on EGFR mutant lung cancer cells with PTEN loss [abstract]. In: Proceedings of the 101st Annual Meeting of American Association for Cancer Research; 2010 Apr 20; Washington D.C. Philadelphia (PA): AACR; 2010. Abstract nr. 3620.
28. Chang TT, Chou TC. Rational approach to the clinical protocol design for drug combinations: A review. Acta Paediatr Taiwan 2000;41: 294-302.
29. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977;252:6438-42.
30. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anti Cancer Res 1999;19:291-9.
31. Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, et al. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer 2012;75:24-9.
32. Xu N, Hegarat N, Black EJ, Scott MT, Hochegger H, Gillespie DA, et al. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol 2010;190:297-305.
33. Strom CE, Johansson F, Uhl-en M, Szigyarto CA, Erixon K, Helleday T, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011;39:3166-75.
34. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22.
35. Fraser M, Zhao H, Luoto KR, Lundin C,Coackley C, Chan N, et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy. Clin Cancer Res 2012;18:1015-27.
36. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009;4:127-50.
37. Syljuasen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005;25:3553-62.
38. Sørensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7: 195-201.
39. Hashimoto Y, Ray Chaudhuri A, Lopes M, Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat Struct Mol Biol 2010;17:1305-11.
40. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res 2011;1:301-27.
41. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinumfree interval. J Clin Oncol 2010;28:2512-9.
42. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
43. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
44. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007;448:561-6.
45. Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol 2011;224: 564-74.